Prospective, Randomized, Monocenter, Double Blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Levosimendan in Intensive Care Patients With Acute Kidney Injury
Status: Active, no longer recruiting
Phase of Trial: Phase II/III
Latest Information Update: 10 Sep 2018
Price : $35 *
At a glance
- Drugs Levosimendan (Primary)
- Indications Acute kidney injury
- Focus Therapeutic Use
- Acronyms LAKIS
- 26 Sep 2016 Planned primary completion date changed from 1 Mar 2017 to 1 Oct 2017.
- 09 Dec 2015 Planned End Date changed from 1 Jun 2017 to 1 Oct 2017 as reported by ClinicalTrials.gov record.
- 09 Dec 2015 Planned primary completion date changed from 1 Jun 2016 to 1 Mar 2017 as reported by ClinicalTrials.gov record.